Related Experiment Video

Updated: Jul 8, 2026

Revealing the Ferroptotic Phenotype of Medulloblastoma
04:01

Revealing the Ferroptotic Phenotype of Medulloblastoma

Published on: March 15, 2024

Targeting ferroptosis resistance in RA fibroblast-like synoviocytes

Burkhard Möller1, Jennifer Amsler2

  • 1Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Burkhard.moeller@insel.ch.

Nature Reviews. Rheumatology
|July 6, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Generation of Induced-pluripotent Stem Cells Using Fibroblast-like Synoviocytes Isolated from Joints of Rheumatoid Arthritis Patients
09:31

Generation of Induced-pluripotent Stem Cells Using Fibroblast-like Synoviocytes Isolated from Joints of Rheumatoid Arthritis Patients

Published on: October 16, 2016

Related Experiment Videos

Last Updated: Jul 8, 2026

Revealing the Ferroptotic Phenotype of Medulloblastoma
04:01

Revealing the Ferroptotic Phenotype of Medulloblastoma

Published on: March 15, 2024

Generation of Induced-pluripotent Stem Cells Using Fibroblast-like Synoviocytes Isolated from Joints of Rheumatoid Arthritis Patients
09:31

Generation of Induced-pluripotent Stem Cells Using Fibroblast-like Synoviocytes Isolated from Joints of Rheumatoid Arthritis Patients

Published on: October 16, 2016

Related Concept Videos

Introduction to Fibroblasts01:09

Introduction to Fibroblasts

Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...

Articles linked to this work by shared authors, journal, and citation graph.

Influence of the shared epitope on the effectiveness of biologic antirheumatic agents in European patients with rheumatoid arthritis.

RMD open·2026

Site-specific articular responses to b/tsDMARDs in rheumatoid arthritis: a longitudinal observational study from the Swiss Clinical Quality Management Registry.

RMD open·2026

Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritis.

RMD open·2026

Effectiveness of TNF inhibitors in patients with very early axial spondyloarthritis, defined as duration of ≤1 year of back pain: longitudinal observational data from the SCQM registry.

RMD open·2026

Discrepancies between routine sacroiliac joint MRI reporting and current expert recommendations in patients with spondyloarthritis.

RMD open·2025

Identification of individuals at high risk of developing rheumatoid arthritis: a balanced random forest model in a cohort of 1544 first-degree relatives.

RMD open·2025

Vaccination considerations in autoimmune rheumatic diseases.

Nature reviews. Rheumatology·2026

Hepatic control of immunometabolism: implications for the pathogenesis, diagnosis and treatment of rheumatic diseases.

Nature reviews. Rheumatology·2026

Evidence-based guidelines for the diagnosis and management of adult-onset IgA vasculitis.

Nature reviews. Rheumatology·2026

Navigating evidence-based recommendations for the management of systemic sclerosis.

Nature reviews. Rheumatology·2026

Advances in the treatment of eosinophilic granulomatosis with polyangiitis.

Nature reviews. Rheumatology·2026

Sex-dependent mechanisms in rheumatic diseases.

Nature reviews. Rheumatology·2026

TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment.

The Journal of experimental medicine·2026

Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC.

Molecular cancer therapeutics·2026

Toward Fit-for-Purpose Data for Drug Assessment in Non-small Cell Lung Cancer: A Core Dataset.

Clinical pharmacology and therapeutics·2026

Regulation of the lncRNA NEAT1 by p53-ΔNp63 crosstalk modulates the DNA damage response and therapeutic efficacy in HNSCC.

Molecular oncology·2026

Payload-Free [89Zr]Zr-DFO*-sq-Enfortumab ImmunoPET for Imaging Nectin-4 Expression in Bladder Cancer.

Molecular pharmaceutics·2026

Preclinical Evaluation of [68Ga]Ga-CS03 as a Novel GPC3-Targeted Probe for Imaging GPC3 in Hepatocellular Carcinoma Models.

Molecular pharmaceutics·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us